One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • Patent number: 11534409
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: December 27, 2022
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Patent number: 11517524
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: December 6, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11505556
    Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 22, 2022
    Assignee: Xalud Therapeutics, Inc.
    Inventors: Raymond A. Chavez, Stephen Collins
  • Patent number: 11497711
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: November 15, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11464772
    Abstract: The invention provides methods for treating chronic and acute pain. For example, the invention provides methods of treating neuropathic and inflammatory pain.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: October 11, 2022
    Assignee: Blue Therapeutics, Inc.
    Inventors: Ajay Yekkirala, David Roberson, Michio Painter
  • Patent number: 11446293
    Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 20, 2022
    Assignee: SpecGX LLC
    Inventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
  • Patent number: 11433063
    Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: September 6, 2022
    Assignee: BELHAVEN BIOPHARMA, INC.
    Inventors: Barry Bleske, Ted William Lanpher
  • Patent number: 11369579
    Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 28, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11351165
    Abstract: It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 7, 2022
    Assignee: LDN Pharma Limited
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11311532
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O'Brien
  • Patent number: 11278544
    Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: March 22, 2022
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Eckard Weber, Michael Alexander Cowley
  • Patent number: 11273133
    Abstract: Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 15, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11234946
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: February 1, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11214577
    Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: January 4, 2022
    Assignee: Humanwell Pharmaceutical US
    Inventors: Subo Liao, Jun Yang, Jie Li, Wentao Du, Lie Li, Jinliang Lv, Zongquan Liao, Hao Zhou, Tianpeng Xie, Jianbo Yu
  • Patent number: 11207317
    Abstract: Methylnaltrexone nasal formulations are disclosed which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 28, 2021
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati
  • Patent number: 11207281
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 28, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11202777
    Abstract: The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 21, 2021
    Assignee: East Carolina University
    Inventors: Kori Brewer, Stefan Clemens
  • Patent number: 11191838
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: December 7, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Patent number: 11185540
    Abstract: Pharmaceutical compositions of one or more opioid antagonists or phosphodiesterase 5 (PDE5) inhibitors are disclosed.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 30, 2021
    Assignee: PARDON MY SCOTCH LLC.
    Inventor: Michael Anthony Pavlovich
  • Patent number: 11185509
    Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Suguru Takaki, Satoshi Minakami, Kotoe Ohta
  • Patent number: 11173209
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 16, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventor: Edward T. Maggio
  • Patent number: 11139056
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 11129826
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: September 28, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11103581
    Abstract: An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 31, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventor: Robert Barnett Jones
  • Patent number: 11083794
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 10, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 11071734
    Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 27, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
  • Patent number: 11045478
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Patent number: 11026939
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: June 8, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
  • Patent number: 11014933
    Abstract: Non-peptide MOR opioid receptor modulators are provided. The compounds exhibit predominantly central activity and are used to treat e.g. substance use disorders, and pain.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: May 25, 2021
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Yan Zhang
  • Patent number: 10987350
    Abstract: Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: April 27, 2021
    Inventors: Hillel Glover, Lillian Hahn
  • Patent number: 10988481
    Abstract: Analogues of 6 ?/?-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: April 27, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Yan Zhang, Dana E. Selley, William Dewey, Hamid Abkarali
  • Patent number: 10973814
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 13, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 10967065
    Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 6, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh Smyth, Ju Du
  • Patent number: 10960077
    Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: March 30, 2021
    Assignee: Intellipharmaceutics Corp.
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 10925870
    Abstract: Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 23, 2021
    Assignee: Ohio State Innovation Foundation
    Inventors: Wolfgang Sadee, John Oberdick
  • Patent number: 10870654
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: December 22, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10865186
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: December 15, 2020
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Patent number: 10828294
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: November 10, 2020
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 10806731
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: October 20, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Elliot Ehrich
  • Patent number: 10799545
    Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the transdermal patch of reservoir type is also taught, which enables things such as Vitamin B12 to become part of the complex deliverable by the inventions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: October 13, 2020
    Assignee: Remy Biosciences, Inc.
    Inventor: Ludwig Weimann
  • Patent number: 10744132
    Abstract: An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 18, 2020
    Assignee: Alar Pharmaceuticals, Inc.
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Jui-Wei Liang
  • Patent number: 10702480
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 7, 2020
    Assignee: OHEMO Life Sciences, Inc.
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 10695342
    Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 30, 2020
    Assignees: ALBANY MOLECULAR RESEARCH, INC., 3ST RESEARCH LLC
    Inventors: Matthew Surman, John K. Thottathil, Kathryn Golden, Paolo Pasetto, Xiaomin Jin, Xiaowu Jiang, Fatoumata Camara
  • Patent number: 10695324
    Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 30, 2020
    Assignee: Washington University
    Inventors: Fumihiko Urano, Simin Lu
  • Patent number: 10695343
    Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Inventors: Noreen Griffin, Fengping Shan, Nicholas Plotnikoff
  • Patent number: 10696684
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: June 30, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10689389
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 23, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10653632
    Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: Monash University
    Inventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
  • Patent number: 10638786
    Abstract: Methods and compositions are provided directed to decreasing visceral fat in subjects. Visceral fat is directly linked to cardiovascular and metabolic disease risk. The methods describe a calorie restricted diet of specific percentages of food elements to be consumed within a specific time period each day. Calorie restriction and nutrient percentages take into consideration average daily normal activity of subjects as well as baseline health metrics including estimated amount of visceral fat. Remarkable results are obtained since visceral fat is targeted for reduction, thereby markedly reducing the risk of cardiovascular and metabolic disease.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: May 5, 2020
    Assignee: Zolighter, LLC
    Inventors: Jessica Barnes, Gerald Dembrowski
  • Patent number: 10632205
    Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: INTELLIPHARMACEUTICS CORP
    Inventors: Isa Odidi, Amina Odidi